Research Pipeline · 16 Nov 2026
CagriSema REDEFINE 9 Phase 3 Results: What Lower-Dose Efficacy Data Mean for the Semaglutide-Amylin Combination Programme
Novo Nordisk's CagriSema achieved approximately 21% average weight loss at 68 weeks using doses below the programme maximum, in Phase 3 REDEFINE 9 data presented at ObesityWeek 2026 and published simultaneously in The Lancet Diabetes & Endocrinology. The findings extend the dose-response profile of the semaglutide–cagrilintide combination and carry implications for procurement teams tracking next-generation GLP-1 research compounds.
9 sources cited
Key takeaways
- Novo Nordisk's investigational CagriSema achieved estimated average weight loss of approximately 21% at 68 weeks in Phase 3 REDEFINE 9, using doses below the maximum studied in the broader REDEFINE programme.
- Results were simultaneously published in The Lancet Diabetes & Endocrinology on 14 November 2026 and presented at ObesityWeek 2026 in Washington, DC.
- REDEFINE 9 is the first Phase 3 weight-management trial to evaluate the fixed-dose combination at sub-maximal doses, providing a broader dose-response picture.
- The data are topline efficacy figures; detailed safety analyses should be evaluated in the published paper before any procurement or formulary decisions are drawn.
- CagriSema is not approved in any jurisdiction; its trajectory through regulatory review in the US is watched closely, with a decision expected in Q4 2026, according to market commentary.
Background: What is CagriSema?
CagriSema is an investigational fixed-dose subcutaneous injection combining two distinct peptide mechanisms. Novo Nordisk describes it as a combination of cagrilintide — a long-acting amylin analogue — and semaglutide, the GLP-1 receptor agonist already approved under the brand names Ozempic, Wegovy, and Rybelsus. The pairing targets two separate satiety pathways: semaglutide acts at the GLP-1 receptor to slow gastric emptying and reduce appetite, while cagrilintide mimics the pancreatic hormone amylin, which regulates postprandial glucose and augments satiety signalling through separate central nervous system pathways.
The combination is administered once weekly by subcutaneous injection, the same route and cadence as Wegovy. This mechanistic duality underpins the hypothesis that additive or synergistic weight loss could be achieved relative to either component alone.
REDEFINE 9: Trial design and primary results
Novo Nordisk announced primary results from the REDEFINE 9 trial on 14 November 2026. The trial enrolled adults with overweight or obesity and evaluated two doses of CagriSema — 1.7 mg/1.7 mg and 1.0 mg/1.0 mg — against placebo over 68 weeks. Crucially, REDEFINE 9 is the first Phase 3 weight-management trial in the REDEFINE programme to assess CagriSema at doses below the 2.4 mg/2.4 mg maximum studied in earlier studies.
Using the efficacy estimand — which reflects treatment effect assuming full adherence — both doses produced estimated average weight loss of 20.7% (1.7 mg/1.7 mg) and 21.0% (1.0 mg/1.0 mg) at week 68, compared with 2.0% in the placebo group. Under the treatment-regimen estimand, which captures weight loss including any off-treatment periods, results were 19.4% and 18.6% respectively, against 4.6% for placebo.
Secondary endpoints were also met: both doses produced significantly greater reductions in abdominal fat as measured by waist circumference, a confirmatory secondary endpoint. Waist circumference reductions were 17.2 cm (1.7 mg/1.7 mg) and 17.5 cm (1.0 mg/1.0 mg), against 3.6 cm with placebo. The results were published simultaneously in The Lancet Diabetes & Endocrinology on 14 November 2026 and presented at ObesityWeek 2026 in Washington, DC, running 14–17 November.
Dose-response context and what REDEFINE 9 adds
The broader REDEFINE clinical programme had previously established the 2.4 mg/2.4 mg dose as the reference point. Topline data presented at Novo Nordisk's Capital Markets Day in September 2026 from REIMAGINE 5 — evaluating CagriSema in adults with type 2 diabetes — indicated CagriSema at 1.0 mg/1.0 mg showed superior weight loss versus tirzepatide 5 mg in that diabetic population, though those were preliminary topline figures without full peer-reviewed safety data.
REDEFINE 9 extends the clinical picture by showing that meaningful weight reduction — in the range of 20–21% — is achievable at doses substantially below the maximum. Novo Nordisk's executive vice president of R&D, Martin Holst Lange, described understanding dose-response relationships as an important part of obesity research, noting that the REDEFINE 9 findings inform how the company continues to develop the cagrilintide-semaglutide combination across the programme.
A secondary analysis presented simultaneously at ObesityWeek from REDEFINE 1 found that 67.8% of patients treated with CagriSema were early responders, achieving an average weight loss of 25.4% by week 68, compared with 17.8% for delayed responders. Notably, women were more likely to be early responders than men, suggesting possible sex-specific differences in treatment response — a signal that may inform future patient stratification in research design.
Regulatory trajectory and market context
CagriSema does not yet hold marketing authorisation in any territory. Market commentary anticipates a US regulatory decision in Q4 2026, though this has not been confirmed by FDA scheduling notices in the sources reviewed. Novo Nordisk's stock rose approximately 3% on 16 November 2026 following the REDEFINE 9 disclosure, reaching DKK 286.1 according to Investing.com.
The GLP-1 receptor agonist class continues to generate very high research demand. Tirzepatide, marketed as Mounjaro and Zepbound, is projected to be the top-selling drug globally in 2026 with estimated sales exceeding $45 billion, while semaglutide products are projected to generate approximately $39.5 billion, according to Evaluate data reported by eMarketer. This commercial backdrop sustains procurement demand for reference standards and research-use semaglutide analogues within regulated laboratory settings.
Procurement and research implications for UK laboratories
For UK research procurement professionals, several considerations arise from the REDEFINE 9 readout:
Reference compound demand. Both semaglutide and cagrilintide will see continued use as reference substances in pharmacological assays as the combination advances. Laboratories working on amylin pathway research or GLP-1/amylin combination models may anticipate increased demand for cagrilintide reference material, which remains a niche but growing procurement category.
Dose-range modelling. The demonstration that sub-maximal doses of the combination produce comparable efficacy to higher doses is clinically relevant to researchers designing dose-finding studies or translational animal models. It suggests the combination's receptor-level pharmacology is sufficiently potent that neither component need be at its ceiling dose for meaningful efficacy — a finding worth incorporating into experimental design parameters.
Regulatory watch. CagriSema's pathway to approval will be followed closely by European regulators as it engages the EMA review process. The EMA Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025), which took legal effect on 1 June 2026, sets the chemistry, manufacturing, and controls framework that any synthetic peptide filing — including fixed-dose combinations containing semaglutide as an active substance — must address. Procurement teams sourcing semaglutide for research programmes should ensure their suppliers' Certificates of Analysis align with these specifications.
Safety data caveat. The 20–21% efficacy figures from REDEFINE 9 derive from the efficacy estimand; the treatment-regimen estimand returned 18.6–19.4%. Full adverse event and tolerability data are published in The Lancet Diabetes & Endocrinology paper (published online 14 November 2026) and should be reviewed before drawing conclusions about the benefit-risk profile at lower doses. Gastrointestinal adverse events are typical of GLP-1 receptor agonist–class drugs, and the amylin component may carry an additional profile that requires careful evaluation in the full dataset.
This article is based on publicly available announcements and peer-reviewed publication data as of 16 November 2026. CagriSema is an investigational compound without marketing authorisation in the UK, EU, or US. Nothing in this briefing constitutes clinical or procurement advice.
Research-grade material, HPLC verified, certificate of analysis with every order.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
More in Research Pipeline
ObesityWeek 2026: EloraTZP Phase 2 Data and Orforglipron's China Approval Signal Lilly's Next Phase in the GLP-1 Pipeline
15 Nov 2026
GLP1R Pharmacogenomics: What New Evidence on Rare Receptor Variants Means for Semaglutide and Tirzepatide Research
14 Nov 2026
Retatrutide Phase 3 Data: What TRIUMPH-4 and TRIUMPH-1-OA Mean for the Triple-Agonist GLP-1 Pipeline
11 Nov 2026